dataset
posted on 2023-04-03, 21:04 authored by Yanwen Jiang, Ana Ortega-Molina, Huimin Geng, Hsia-Yuan Ying, Katerina Hatzi, Sara Parsa, Dylan McNally, Ling Wang, Ashley S. Doane, Xabier Agirre, Matt Teater, Cem Meydan, Zhuoning Li, David Poloway, Shenqiu Wang, Daisuke Ennishi, David W. Scott, Kristy R. Stengel, Janice E. Kranz, Edward Holson, Sneh Sharma, James W. Young, Chi-Shuen Chu, Robert G. Roeder, Rita Shaknovich, Scott W. Hiebert, Randy D. Gascoyne, Wayne Tam, Olivier Elemento, Hans-Guido Wendel, Ari M. Melnick A list of primer sequences used in Figure 5.
Funding
American Society of Hematology
Leukemia and Lymphoma Society
UCSF
AACR
Ministry of Science and Technology
Swedish Research Council
Terry Fox
BC Cancer
National Cancer Institute
Swim Across America
NIH
NSF
NCI
American Cancer Society
Lymphoma Research Foundation
Cycle for Survival, Functional Genomics Initiative
Commonwealth Foundation
Memorial Sloan-Kettering Cancer Center
LLS
History
ARTICLE ABSTRACT
Somatic mutations in CREBBP occur frequently in B-cell lymphoma. Here, we show that loss of CREBBP facilitates the development of germinal center (GC)–derived lymphomas in mice. In both human and murine lymphomas, CREBBP loss-of-function resulted in focal depletion of enhancer H3K27 acetylation and aberrant transcriptional silencing of genes that regulate B-cell signaling and immune responses, including class II MHC. Mechanistically, CREBBP-regulated enhancers are counter-regulated by the BCL6 transcriptional repressor in a complex with SMRT and HDAC3, which we found to bind extensively to MHC class II loci. HDAC3 loss-of-function rescued repression of these enhancers and corresponding genes, including MHC class II, and more profoundly suppressed CREBBP-mutant lymphomas in vitro and in vivo. Hence, CREBBP loss-of-function contributes to lymphomagenesis by enabling unopposed suppression of enhancers by BCL6/SMRT/HDAC3 complexes, suggesting HDAC3-targeted therapy as a precision approach for CREBBP-mutant lymphomas.Significance: Our findings establish the tumor suppressor function of CREBBP in GC lymphomas in which CREBBP mutations disable acetylation and result in unopposed deacetylation by BCL6/SMRT/HDAC3 complexes at enhancers of B-cell signaling and immune response genes. Hence, inhibition of HDAC3 can restore the enhancer histone acetylation and may serve as a targeted therapy for CREBBP-mutant lymphomas. Cancer Discov; 7(1); 38–53. ©2016 AACR.See related commentary by Höpken, p. 14.This article is highlighted in the In This Issue feature, p. 1
